Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes

Natalia López-Andrés1, Carmen Iñigo, Idoia Gallego

  • 1Centre for Applied Medical Research, Department of Cardiology and Cardiovascular Surgery, University Clinic, Universidad de Navarra, Avenida Pio XII, 55, 31008 Pamplona, Spain.

Endocrinology
|June 21, 2008
PubMed

Insights

Aldosterone (ALDO) directly increases cardiotrophin-1 (CT-1) expression in heart cells, a key step in ALDO-induced cardiac hypertrophy. Blocking CT-1 signaling prevents this hypertrophic effect in vitro and in vivo.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Endocrinology

Background:

  • Aldosterone (ALDO) is implicated in cardiac hypertrophy through undefined nonhemodynamic pathways.
  • Cardiotrophin-1 (CT-1) is a cytokine known to promote cardiomyocyte hypertrophy.

Purpose of the Study:

  • To investigate if aldosterone induces Cardiotrophin-1 (CT-1) expression in cardiomyocytes.
  • To determine if CT-1 mediates aldosterone-induced cardiomyocyte hypertrophy.

Main Methods:

  • Quantification of CT-1 mRNA and protein expression using RT-PCR and Western blot in HL-1 cardiomyocytes.
  • Measurement of cardiomyocyte area as an index of hypertrophy.
  • In vivo studies in C57BJ6 wild-type and CT-1-null mice following aldosterone injection.

Main Results:

  • Aldosterone significantly increased CT-1 mRNA and protein expression in HL-1 cells in a dose-dependent manner.
  • Aldosterone-induced CT-1 expression and cardiomyocyte hypertrophy were blocked by receptor antagonists, actinomycin D, and p38 MAPK inhibition.
  • Blocking CT-1 signaling prevented aldosterone-induced overexpression of alpha-sarcomeric actin and c-fos, and cell size increase.
  • Aldosterone acutely increased myocardial CT-1 expression in wild-type mice but not in CT-1-null mice, with associated increases in ANP and c-fos mRNA.

Conclusions:

  • Aldosterone induces Cardiotrophin-1 expression in cardiomyocytes via both genomic and non-genomic mechanisms.
  • Up-regulation of CT-1 is a significant factor in the direct hypertrophic effects of aldosterone on cardiomyocytes.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...